FDA Drug Label & Ingredient
Review Services
Drug labeling requirements depend on the product's legal marketing pathway and type. Covered OTC drug labels generally must follow the Drug Facts content and format requirements in 21 CFR 201.66 and any applicable OTC monograph conditions. Prescription labeling is governed by different requirements, including 21 CFR 201.56 and 201.57 for PLR-format prescribing information where applicable. A label review can identify format, ingredient, warning, direction, claim, and required-statement issues, but it does not make an unapproved or otherwise unlawful drug marketable.
Send your current label artwork and complete formulation. We review the label against the requirements that apply to the product, identify gaps before print or launch, and provide correction guidance you can give directly to your designer or regulatory team.
*After complete label artwork, formulation, and product details are received; complex products can require additional time.
A Compliant Drug Label Starts With the Product's Regulatory Pathway
A label can be beautifully designed and still be noncompliant if the active ingredient, indication, dosage, warnings, Drug Facts structure, prescription labeling, or marketing claims do not match the legal pathway for the product.
For OTC monograph drugs, the review starts with the applicable monograph conditions and the Drug Facts requirements. For approved prescription or approved OTC products, the approved application and labeling control what can be marketed. Other drug categories can require different analysis.
- Confirm whether the product is OTC monograph, approved application, prescription, or another drug category
- Review active ingredient identity, strength, dosage form, route, and intended use
- Check Drug Facts or prescription labeling content and format as applicable
- Review required warnings, directions, uses, storage, identity, and net-quantity statements
- Flag claims or design choices that could create false, misleading, or off-pathway labeling risk
An attractive, technically formatted label cannot legalize an active ingredient, claim, dosage, or product that does not qualify under its intended OTC monograph or approved-application pathway. We separate label-format review from the larger question of whether the product itself may be lawfully marketed.
Information Needed for a Drug Label & Ingredient Review
The review is only as accurate as the product information provided. Final artwork plus full formulation and regulatory context produce the strongest result.
Complete Label Artwork
Provide the current U.S. label, carton, container, insert, Drug Facts panel, or prescribing-information components that will actually be marketed.
- Principal display panel
- Drug Facts or Rx labeling
- Carton and immediate container
- Package insert / patient labeling if applicable
- Current revision/version
Complete Formulation
We need enough formulation detail to verify ingredient declarations and compare the product against the intended regulatory pathway.
- Active ingredients and strengths
- Inactive ingredients
- Dosage form and route
- Product strength/concentration
- Special excipients or color additives when relevant
Marketing & Regulatory Status
The applicable rule depends on whether the product is an OTC monograph drug, approved drug, prescription drug, or another category.
- OTC monograph / administrative-order category
- NDA / ANDA number if applicable
- Rx or OTC status
- Existing NDC/listing information if available
- Manufacturer / labeler information
Claims & Intended Use
Claims can change the regulatory analysis. Provide the wording used on packaging, websites, marketplaces, brochures, and other labeling materials when relevant.
- Uses / indications
- Directions and dosing
- Front-panel claims
- Comparative or clinical claims
- Website / marketplace claims when requested
Four Regulatory Anchors We Check
Different products require different sections of FDA's labeling framework.
Drug Label Review in 4 Steps
We review the label against the requirements that actually apply to the product, then give your team specific corrections rather than generic design comments.
Submit Label & Product Details
Send artwork, complete formulation, intended use, dosage form, strength, regulatory pathway, and existing FDA information if available.
Regulatory & Label Review
We identify the applicable pathway and review format, ingredients, claims, warnings, directions, required statements, and consistency.
Written Findings
Receive a written review identifying the issues found and practical recommendations for correction.
Post-Revision Verification
After your team applies the corrections, we perform one standard verification of the revised label within scope.
What the $249 Standard Drug Label Review Covers
The exact checklist depends on the drug type and materials submitted, but the standard review focuses on the following areas.
Regulatory Pathway Check
Identify whether the supplied information points to an OTC monograph, approved application, prescription, or other drug-labeling framework.
Principal Display Panel
Review identity, prominence, net quantity, required front-panel information, and claim presentation as applicable.
Drug Facts / Rx Format
Check the applicable content, headings, sequence, typography/format concepts, and required prescribing-information structure.
Active Ingredients
Review active ingredient identity, strength/concentration, purpose, and consistency with the intended pathway and label.
Inactive Ingredients
Review inactive ingredient declaration and presentation based on the applicable drug-labeling requirements and submitted formulation.
Uses, Warnings & Directions
Check intended-use language, dosing directions, required warnings, special population statements, and related content where applicable.
Claims & Misbranding Risk
Flag statements that appear inconsistent with the applicable monograph, approved labeling, or general false/misleading-labeling standards.
Written Corrections + Recheck
Provide written findings and one standard post-revision verification after the identified corrections are applied.
OTC Drug Facts vs Prescription Labeling
Both are drug labeling, but the governing format and regulatory basis are different.
| Factor | OTC Drug Facts | Prescription Labeling |
|---|---|---|
| Primary Format | Standardized Drug Facts format for covered OTC drugs | Prescribing Information format applicable to the product/application |
| Core Rules | 21 CFR 201.66 + applicable OTC monograph/order or approved OTC application | 21 CFR 201.56/201.57 where PLR applies; § 201.80 may apply to older-format labeling |
| Marketing Basis | Applicable OTC monograph under § 505G or an approved application | Generally an approved NDA/ANDA/BLA or another lawful prescription-drug basis |
| Key Review Areas | Active ingredient, purpose, uses, warnings, directions, inactive ingredients, other information, format | Highlights/Contents/Full Prescribing Information, indications, dosing, contraindications, warnings, adverse reactions, and other required sections as applicable |
| Label Review = Approval? | No | No |
Drug Label Review vs Drug Listing / NDC
A compliant label and a correct FDA listing are related, but they are not the same filing.
| Factor | Drug Label & Ingredient Review | Drug Listing / NDC |
|---|---|---|
| Purpose | Assess label content, format, formulation declarations, warnings, claims, and corrections | Submit required drug product information electronically in FDA's drug listing system |
| Typical Deliverable | Written findings + correction recommendations + standard revision recheck | Drug listing SPL / NDC-related record as applicable |
| Does One Replace the Other? | No | No |
| FDA Approval? | A consultant review is not FDA approval | Listing/NDC assignment does not denote FDA approval |
| When Needed | Before print/launch and after meaningful label/formulation changes | When Part 207 drug listing requirements apply and when listing updates are required |
Internal Artwork Check vs Regulatory Drug Label Review
A design proof catches visual problems. A regulatory review asks whether the product's labeling matches the legal requirements that apply.
| Factor | Internal / Design Proof | Regulatory Label Review |
|---|---|---|
| Primary Focus | Brand, spelling, layout, print quality, dimensions | Regulatory pathway, required content, claims, ingredients, warnings, directions, format |
| OTC Monograph Analysis | Only if the internal reviewer has that expertise | Reviewed when relevant to the product |
| Prescription Labeling Rules | Not normally part of a graphic-design proof | Reviewed when the submitted product requires Rx labeling analysis |
| Written Regulatory Findings | Usually no | Yes, within the agreed scope |
| Post-Revision Verification | Internal proofreading as chosen by company | One standard recheck included in our $249 review scope |
Drug Labeling Terms You Should Know
These terms help separate the label itself from the product's marketing pathway and FDA listing records.
Standardized OTC drug labeling format under 21 CFR 201.66 for covered nonprescription products.
Conditions under which a category of OTC drugs may be marketed without an approved application when all applicable requirements are met.
The post-CARES Act mechanism FDA uses to establish or modify OTC monograph conditions under section 505G.
Physician Labeling Rule format for prescribing information governed primarily by 21 CFR 201.56 and 201.57 where applicable.
Principal Display Panel — the portion of a package most likely to be displayed or examined under customary retail conditions.
A drug component intended to furnish pharmacological activity or another direct effect in diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect structure/function.
A drug component other than an active ingredient; the declaration and role must still be reviewed for the applicable product.
The legally recognized/nonproprietary drug name used where FDA labeling rules require the established name.
A statutory violation category that can include false/misleading labeling or failure to include required labeling information.
National Drug Code — a drug identifier used in FDA's listing framework; an NDC does not itself mean the drug is FDA-approved.
Structured Product Labeling — FDA's XML-based format used for drug registration/listing and electronic labeling information.
A broader legal concept than the physical package label and can include accompanying materials depending on the facts.
Drug Label Problems We Commonly Flag
Not every issue below applies to every drug, but these are common reasons a label needs regulatory correction.
Wrong OTC Monograph Pathway
The formulation, strength, indication, route, dosage, or claim does not fit the monograph conditions the company expects to use.
Drug Facts Content or Format Errors
Required headings, sequence, warnings, directions, ingredient information, or formatting do not match the applicable Drug Facts rules.
Active Ingredient / Strength Mismatch
The declared active ingredient, strength, purpose, or directions are inconsistent with formulation records or the applicable pathway.
Off-Pathway Claims
Front-panel or marketing claims go beyond the use/indication supported by the monograph or approved labeling.
Incomplete Warnings or Directions
Product-specific or pathway-required warnings/directions are missing, abbreviated incorrectly, or inconsistent with intended use.
Foreign-Language Inconsistency
When a label uses another language, required information is not handled consistently with the applicable drug-language requirements and exceptions.
Expiration / Lot Statements Treated as Universal
Expiration dating and traceability requirements are applied without considering the specific drug, CGMP rule, and regulatory exceptions that can apply.
Calling the Product “FDA Approved” Based on Listing
An NDC, listing, establishment registration, or consultant label review is used as evidence of FDA product approval even though those are separate concepts.
Related FDA Drug Registration & Listing Services
These services directly support the drug-registration, listing, identifier, and import work that can accompany a label review.
Drug Establishment Registration
Registration and annual renewal support for covered domestic and foreign drug establishments.
Drug Labeler Code Registration
Prepare the SPL Labeler Code request and post-assignment confirmation step before NDC/listing use.
NDC / Drug Product Listing
Prepare product/package NDC data and the associated SPL drug-listing submission.
Drug DUNS Assistance
Help resolve DUNS information used in FDA drug establishment, Labeler Code, and listing workflows.
Drug U.S. Agent Services
U.S. Agent representation for covered foreign drug establishments under 21 CFR Part 207.
Drug Listing Verification & Maintenance
Review current FDA listing information and maintain product records without representing listing as product approval.
Drug Master File Support
DMF support for confidential manufacturing, chemistry, or ingredient information when a DMF is appropriate.
Drug Import Alert Assistance
Review drug DWPE / Import Alert issues, evidence, corrective action, and the alert-specific FDA pathway.
FDA Drug Label & Ingredient Review FAQs
Answers about Drug Facts, OTC monographs, prescription labeling, ingredients, warnings, claims, NDCs, expiration dating, multilingual labels, homeopathic drugs, revision checks, and pricing.
What does an FDA drug label review check?
The review checks the labeling requirements that apply to the specific product and can include regulatory pathway, Drug Facts or prescription labeling format, active and inactive ingredients, uses, warnings, directions, claims, principal display panel information, required statements, and consistency with the submitted formulation and FDA records.
How much does the drug label review cost?
Our standard professional fee is $249 per drug product label review. The standard scope includes written findings and one post-revision verification of the corrected label.
How long does a drug label review take?
Our typical service target is 3–7 business days after complete artwork, formulation, and product information are received. Complex products, incomplete information, or questions about marketing status can require additional time.
Does every OTC drug need a Drug Facts panel?
FDA's Drug Facts requirements apply broadly to OTC drug products, but the specific labeling analysis should account for the product, package, and any applicable exceptions or special provisions. We review the actual product rather than assuming one template applies in every situation.
What regulation governs the OTC Drug Facts label?
The standardized OTC Drug Facts content and format requirements are primarily in 21 CFR 201.66.
What sections are typically in the Drug Facts panel?
Drug Facts generally includes active ingredient and purpose, uses, warnings, directions, other information, inactive ingredients, and other required information arranged under the applicable FDA format rules.
What is an OTC monograph?
An OTC monograph establishes conditions such as active ingredients, uses, doses, routes, labeling, and sometimes testing under which a category of nonprescription drugs can be marketed without an approved drug application when all applicable requirements are met.
Did the CARES Act change the OTC monograph system?
Yes. Section 505G of the FD&C Act modernized the OTC monograph system and FDA now uses an administrative-order process to establish or modify many monograph conditions.
Can a label review tell me whether my OTC product qualifies under a monograph?
The review can flag whether the submitted formulation, claims, strengths, directions, or other information appear inconsistent with the intended monograph pathway. A complex eligibility or formulation analysis can require additional regulatory work beyond a basic artwork review.
Does FDA pre-approve OTC monograph labels?
No. OTC monograph drugs that meet section 505G, the applicable monograph conditions, and other requirements can generally be marketed without an approved NDA for that individual product. That does not mean FDA pre-approved the specific label.
Can you review prescription drug labeling too?
Yes. Prescription labeling can be reviewed against the requirements that apply to the specific product, including 21 CFR 201.56 and 201.57 for PLR-format prescribing information where applicable. Some older-format labeling can involve 21 CFR 201.80.
Is PLR format required for every prescription drug label ever marketed?
Not necessarily. FDA maintains PLR-format requirements and also recognizes older-format labeling under 21 CFR 201.80 for certain products. The applicable format depends on the product and regulatory history.
Can a consultant change approved prescription labeling without FDA approval?
No. For an approved drug, labeling changes are governed by the approved application and applicable supplement/reporting requirements. A consultant review does not replace the sponsor's FDA submission or approval obligations.
Do you review active ingredients?
Yes. We review the active ingredient name, strength or concentration, purpose, dosage form, route, and consistency with the intended regulatory pathway and the materials provided.
Do you review inactive ingredients?
Yes. Inactive ingredient declaration and presentation are reviewed based on the applicable drug-labeling requirements and the complete formulation supplied by the client.
Are inactive ingredients in OTC Drug Facts listed alphabetically?
Under 21 CFR 201.66, inactive ingredients are generally listed in alphabetical order in the Drug Facts panel, subject to the applicable requirements and product-specific circumstances.
Do you review warnings and directions?
Yes. Warnings and directions are core review areas because the required language can depend on the product category, active ingredient, dosage, intended use, monograph/order, or approved labeling.
Do you review marketing claims?
Yes, when the claims are supplied as part of the review. We flag claims that appear inconsistent with the applicable monograph, approved labeling, intended use, or general false-or-misleading labeling standards.
Does a label review guarantee FDA will never object to the product?
No. A professional review reduces avoidable labeling errors but cannot guarantee an FDA inspection, import, enforcement, or marketplace outcome. FDA can evaluate the complete product, manufacturing, marketing status, records, and labeling.
Does a label review make my drug FDA-approved?
No. A consultant label review is not FDA approval, clearance, certification, or endorsement.
Does an NDC mean the drug is FDA-approved?
No. FDA states that an NDC or drug listing does not by itself mean the drug is approved.
Can I use an NDC listing as proof that the label is compliant?
No. FDA's listing databases contain information submitted by companies, and listing is separate from a regulatory determination that the product or label complies with all applicable requirements.
Do dietary supplements use a Drug Facts panel?
No. Dietary supplements are labeled under the food/supplement framework and generally use a Supplement Facts panel rather than a Drug Facts panel.
Can a cosmetic use a Drug Facts panel?
A cosmetic-only product does not use the OTC Drug Facts framework. If claims or ingredients cause the product to be a drug as well as a cosmetic, the applicable drug requirements must also be evaluated.
What about sunscreen?
Sunscreen marketed as an OTC drug must satisfy the applicable OTC drug requirements, including the relevant monograph/order conditions, Drug Facts labeling, and other applicable requirements. The precise formulation and claims should be reviewed.
What about hand sanitizer?
Hand sanitizers can be drug products depending on their intended use and claims. The applicable legal marketing status and labeling should be reviewed rather than assuming that any formula can be marketed by simply adding a Drug Facts panel.
Are homeopathic products FDA-approved because they are homeopathic?
No. FDA states that there are no FDA-approved products labeled as homeopathic. Homeopathic products remain subject to federal drug requirements, and FDA applies a risk-based enforcement approach to unapproved homeopathic drugs.
Does a homeopathic drug automatically qualify under an OTC monograph?
No. Homeopathic status is not an OTC monograph approval pathway. FDA states that homeopathic products are subject to the same statutory requirements related to approval, adulteration, and misbranding as other drugs.
Does every drug require an expiration date on the label?
Drug expiration dating is governed by CGMP and product-specific requirements, and FDA recognizes limited exceptions. For example, 21 CFR 211.137 contains exceptions for certain OTC products and homeopathic drugs. We avoid treating expiration-date requirements as identical for every product.
Does every drug package require the same lot or control number presentation?
Drug traceability and packaging controls are governed by applicable CGMP and labeling requirements. The correct presentation depends on the product and packaging configuration rather than one universal artwork rule.
Can my U.S. drug label be Spanish-only?
FDA's drug labeling language rules generally require required information in English, but 21 CFR 201.15 includes circumstances involving U.S. territories where another language is predominant and also governs multilingual labeling. Puerto Rico and other territory-specific situations should be reviewed before assuming English is always the only permissible presentation.
If I use Spanish and English, do I need to translate all required information?
When labeling contains a foreign-language representation, 21 CFR 201.15 can require the required label information to appear in the foreign language as well. The exact application should be checked against the product and distribution circumstances.
Does Drug Facts have to appear on both carton and immediate container?
The answer depends on the packaging configuration and applicable OTC labeling rules, including small-package and other provisions. We review the actual carton/container set rather than applying a blanket 'both in all cases' rule.
Do you review country-of-origin or Made in USA claims?
We can flag those claims as part of a label review, but country-of-origin and U.S.-origin claims can involve CBP and FTC rules in addition to FDA drug-labeling requirements. Specialized origin analysis may be outside the basic drug-label review scope.
Do you review color additives and other formulation ingredients?
We review the submitted ingredient list for labeling and obvious regulatory issues within scope. A full color-additive, excipient safety, compendial, or formulation-permissibility assessment may require separate research.
Will you redesign my label?
The standard $249 service is a regulatory review, not a graphic-design or artwork-redesign service. We provide written corrections that your designer can implement.
Is one revised-label recheck included?
Yes. One standard post-revision verification is included in the $249 review scope. Additional revision rounds or major product changes can require a new or expanded review.
Do I need to update my FDA drug listing when the label changes?
Drug listing information must be kept current under Part 207. Whether a particular change requires a listing update depends on the change and the applicable listing requirements. A label review and an SPL listing update are separate services.
Can you review a foreign manufacturer's label before U.S. import?
Yes. We can review labeling intended for the U.S. market for foreign manufacturers, repackers, relabelers, distributors, and brand owners. Foreign drug import compliance also involves separate establishment, listing, marketing-status, cGMP, and import requirements.
What should I send to start?
Send the full label artwork, complete active/inactive ingredient list with strengths, dosage form, route, intended use, product category, OTC monograph or NDA/ANDA information if known, current NDC/listing information if available, and any claims you want reviewed.
Request a Drug Label & Ingredient Review
Tell us the drug type, product name, country, regulatory pathway if known, and what you need reviewed. After we receive the inquiry, we will confirm the materials needed for the label review.